Overseas Growth Centered on North America and Expansion of Treatment-Support Products
First written in FY2017. 6 of 16 entries say "Advanced", first in FY2022. Latest entry: 2026-08-06.
The whole theme swung hardest in 2026: 1 of 6 companies on the "Worse" side.
4 other companies' latest entry also says "Advanced".
- 2026-08-06AdvancedRevision of earnings forecasts
「Overseas sales increased substantially, partly due to the effect of new products.」
The overseas growth of the medical systems business was specifically reflected in regional sales increases in North America, Europe, China and other Asian regions. - FY2026-H1AdvancedAnnual report
「Sales increased in North America and other Asian regions, driven by the impact of new products.」
The specific growth of overseas medical equipment was shown by sales in North America increasing 6.7% year on year and sales in other Asian regions increasing 8.1%, driven by new products. - FY2025-H1AdvancedAnnual report
「Meanwhile, X-ray TV systems increased in North America as hospitals' operating environments improved, while angiography systems increased in other parts of Asia, reflecting greater recognition in the Philippines and elsewhere through technical exchange meetings. In addition, the services business increased in Japan, North America and other parts of Asia.」
Specific overseas growth in medical equipment was shown by increases in North American sales of X-ray TV systems, angiography systems in the Philippines and other markets, and service operations in multiple regions. - FY2024ReframedAnnual report
「In Japan, the new angiography system equipped with the world's first AI-based image processing technology increased, creating expectations for future growth, although the decline in supplementary budgets and the reaction to fewer large projects had an impact. Overseas, angiography systems increased as their low radiation exposure and high image quality were well received.」
Growth overseas and product expansion in medical equipment are centered on increased overseas sales of low-dose, high-image-quality angiography systems, while the description has changed to reflect lower domestic revenue due to a decline in supplementary budgets and the absence of large projects. - FY2024-Q3RestatedAnnual report
「The medical equipment business recorded lower sales in Japan and higher sales overseas.」
In the medical equipment business, the regional mix in which higher overseas revenue is outweighed by lower domestic revenue has continued. - FY2024-Q1ReframedAnnual report
「Revenue in the medical equipment business declined in Japan but increased overseas.」
For overseas growth in the medical equipment business, the regional mix showed continued revenue growth overseas, while revenue declined in Japan due to a reactionary decline in tracking systems for radiation therapy and restrained investment. - FY2023AdvancedAnnual report
「In the overseas business, efforts to resolve issues together with partners resulted in higher sales in all major regions. The overseas sales ratio rose to 56.2%, up 3.2 percentage points from the previous fiscal year.」
Overseas operations recorded higher revenue in all major regions, and the overseas revenue ratio rose 3.2 percentage points to 56.2%. - FY2023-Q3AdvancedAnnual report
「The near-patient-operation X-ray TV system introduced for the US market increased.」
Growth overseas and product expansion in the medical equipment business are reflected in a specific increase in the close-control X-ray TV systems introduced for the US market. - FY2023-Q1RestatedAnnual report
「The medical equipment business recorded higher sales both in Japan and overseas, alongside the recovery in capital investment by medical institutions.」
The increase in revenue in the medical equipment business, including overseas growth accompanying the recovery in capital investment by medical institutions in Japan and overseas, has been reconfirmed. - FY2022AdvancedAnnual report
「The new angiography system launched in April improved value-added features, including reduced patient burden and ease of use, through AI-based image processing and other technologies. The company is also actively expanding its service business and developing and selling diagnostic support applications and software, with the aim of improving profitability.」
Specific plans have emerged for the launch of a new angiography system and expansion into AI image processing, services, and diagnostic support software. - FY2021ReframedAnnual report
「The Group will expand sales of X-ray TV systems, whose profitability has been improving, by strengthening the business through direct sales in the United States and other measures. It is also working to establish a new business model combining analytical and medical applications, including the sale of fully automated PCR testing systems developed using technologies from the measuring instruments business to clinics.」
The description has expanded from its previous focus on new products for the US market and angiography systems to business strengthening that includes direct sales in the US, fully automated PCR testing systems, and the integration of analytical and medical businesses. - FY2021-Q3RestatedAnnual report
「Mobile X-ray imaging systems increased, mainly overseas, for diagnosing pneumonia caused by COVID-19. Other models, however, performed poorly as capital investment was postponed or frozen because medical institutions prioritized measures against COVID-19 and their profitability deteriorated.」
The expansion of overseas mobile X-ray systems for infectious disease diagnosis continues, while other models remain under severe conditions due to postponed or frozen capital investment. - FY2021-Q2RestatedAnnual report
「Mobile X-ray imaging systems increased, mainly overseas, for diagnosing pneumonia caused by COVID-19. Other models, however, performed poorly as capital investment was postponed or frozen because medical institutions prioritized measures against COVID-19 and their profitability deteriorated.」
The policy and business mix of expanding overseas mobile X-ray radiography systems for infectious disease diagnosis, while other products remain challenging because hospitals have postponed or frozen capital investment, continues. - FY2021-Q1ReframedAnnual report
「Mobile X-ray imaging systems expanded mainly overseas for use in diagnosing COVID-19 pneumonia, but other models remained weak as medical institutions focused on countermeasures against COVID-19 and their earnings deteriorated due to the spread of the virus.」
In the Medical Equipment segment, the description has shifted from a focus on new products for the United States, angiography systems and aftermarket operations to a structure in which overseas mobile X-ray imaging systems are expanded for infectious disease diagnosis, while other models remain challenging. - FY2020RestatedAnnual report
「The Group will continue to focus on expanding the aftermarket business, as well as increasing sales of new X-ray TV systems tailored to the U.S. market, the target market, and angiography systems.」
The medical equipment business continues to focus on the aftermarket, new X-ray TV system products specialized for the US market, and angiography systems. - FY2017First statedAnnual report
「① Business growth in priority overseas regions centered on North America ② Expansion of the product lineup centered on treatment-support products ③ Strengthening the earnings structure through expansion of the aftermarket business」
First listing of the medical equipment business’s key initiatives covering priority regions, product areas, and means of improving profitability.